Results 171 to 180 of about 50,615 (267)

Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults [PDF]

Introduction Volumes of hippocampus and cholinergic basal forebrain are associated with delayed recall performance and may modulate the effect of a muscarinic receptor antagonist on delayed recall in healthy volunteers Methods We studied 15 older adults ...
Bruno, D, Grothe, M, Nierenberg, J, Pomara, N, Teipel, S   +4 more
core  

Dysregulation of CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Causes Urinary Bladder Dysfunction with Abnormal Smooth Muscle Contractility

The FASEB Journal, Volume 40, Issue 7, 15 April 2026.
Abnormal extracellular ATP levels cause lower urinary tract symptoms (LUTS). Here, we demonstrate that overexpression of ENTPD1 (CD39TG)—an ATP/ADP converting enzyme—reduces voiding frequency while increasing void volume. Conversely, ENTPD1 deficiency results in frequent, small‐volume voiding.
Zhaobo Luo, Huan Chen, Ali Wu, Weipu Mao, Sagar Barge, Seth L. Alper, Simon C. Robson, Weiqun Yu   +7 more
wiley   +1 more source

Quantitative Analysis of Muscarinic Antagonist Atropine and Tiotropium in Microvolume Plasma Using Liquid Chromatography-Mass Spectrometry: Application for Pharmacokinetic Studies. [PDF]

J Anal Methods Chem
Trancart M, Penot M, Meesemaecker G, Boffy R, Hanak AS, Calas AG, Taudon N.   +6 more
europepmc   +1 more source

Corrigendum to "Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium". [PDF]

Biomed Res Int, 2019
Hamelmann E.
europepmc   +1 more source

Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry. [PDF]

Respir Res
Sugawara H, Saito A, Yokoyama S, Chiba H.   +3 more
europepmc   +1 more source

5-HT2A receptor enhancement of contractile activity of the porcine urothelium and lamina propria [PDF]

, 2016
Alexander, Andersson, Baxter, Berger, Birder, Blakeman, Blanco, Bschleipfer, Chapple, Gillespie, Ikeda, Imamura, Kanai, Lecci, Liang, Masunaga, Matsumoto-Miyai, Moro, Moro, Moro, Moro, Pfeiffer, Rahnama'i, Rahnama'i, Recio, Rekik, Sadananda, Sellers, Sleight, Wang   +29 more
core   +1 more source

Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial). [PDF]

Circ Rep
Hayashi H, Ito S, Fukuda H, Sata M, Abe Y, Fujimoto K, Fukuda D, Hanajima Y, Horii M, Ikehara N, Inoko M, Izumi C, Izumiya Y, Nakayama T, Sozu T, Toyoda S, Watanabe M, Yokoi M, Kitakaze M.   +18 more
europepmc   +1 more source

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. [PDF]

Int J Chron Obstruct Pulmon Dis, 2018
Yamada H, Hida N, Hizawa N.
europepmc   +1 more source

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers. [PDF]

Int J Chron Obstruct Pulmon Dis, 2020
Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J.   +4 more
europepmc   +1 more source

The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro. [PDF]

Respir Res
Matera MG, Rinaldi B, Calabrese C, Belardo C, Calzetta L, Cazzola M, Page C.   +6 more
europepmc   +1 more source